Compare PGR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGR | BSX |
|---|---|---|
| Founded | 1937 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4B | 149.7B |
| IPO Year | N/A | 1992 |
| Metric | PGR | BSX |
|---|---|---|
| Price | $234.67 | $92.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | ★ $270.96 | $124.53 |
| AVG Volume (30 Days) | 3.0M | ★ 9.7M |
| Earning Date | 01-28-2026 | 10-22-2025 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | 32.41 | ★ 54.68 |
| EPS | ★ 18.22 | 1.87 |
| Revenue | ★ $85,166,000,000.00 | $19,349,000,000.00 |
| Revenue This Year | $12.30 | $21.05 |
| Revenue Next Year | $8.26 | $11.43 |
| P/E Ratio | ★ $12.89 | $49.51 |
| Revenue Growth | 18.35 | ★ 21.61 |
| 52 Week Low | $199.90 | $85.98 |
| 52 Week High | $292.99 | $109.50 |
| Indicator | PGR | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 33.35 |
| Support Level | $222.44 | $91.45 |
| Resistance Level | $229.56 | $93.89 |
| Average True Range (ATR) | 3.98 | 2.10 |
| MACD | 0.66 | -0.83 |
| Stochastic Oscillator | 98.10 | 10.42 |
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.